Pursuant to regulation 30 (read with part A of Schedule III) and other applicable provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"), ....
INNOVACAP · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Innova Captab Limited reported strong full-year results for FY2026. Consolidated revenue grew 31% to Rs 16,300.18 million from Rs 12,436.76 million, driven by the pharmaceutical business. Profit after tax (PAT) increased 9.9% to Rs 1,409.17 million versus Rs 1,282.58 million last year. Standalone revenue rose 35% to Rs 12,958.14 million, but standalone PAT declined 6.5% to Rs 836.92 million from Rs 894.70 million due to higher costs at the holding company level. The auditor BSR & Co. LLP issued an unmodified (clean) opinion on both consolidated and standalone results. The company declared an interim dividend of Rs 2 per share in January 2026 and amended its Related Party Transactions policy during the board meeting.
The stock shows solid revenue growth above 30% indicating strong business momentum, though standalone PAT decline may concern some investors. The clean audit opinion is positive and no going concern or qualified opinion issues were raised by auditors.